InvestSMART

Cynata Therapeutics Limited (ASX: CYP) - Announcements

Current share price for CYP : $0.014 0.002 (16.67%)+

ASX company news and announcements for Cynata Therapeutics Limited (CYP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cynata Therapeutics Limited (CYP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cynata Therapeutics Limited (CYP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cynata Therapeutics Limited (CYP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$3 Encouraging Early Data-Cynata Clinical Trial Proceeds 22 Jan 2018 12:17PM $0.590 $0.014 fallen by 97.63%
$3 Trading Halt 22 Jan 2018 9:33AM $0.590 $0.014 fallen by 97.63%
$3 Release of Securities from Voluntary Escrow 11 Jan 2018 7:08PM $0.585 $0.014 fallen by 97.61%
$3 Interview with Cynata Co-Founder Professor Slukvin 11 Jan 2018 12:04PM $0.585 $0.014 fallen by 97.61%
$3 End of Year Newsletter & 2018 Outlook 18 Dec 2017 9:52AM $0.595 $0.014 fallen by 97.65%
$3 Cynata Receives $1.3m R&D Tax Incentive Refund 14 Dec 2017 11:39AM $0.595 $0.014 fallen by 97.65%
$3 Final Preclinical Asthma Study Confirms Efficacy 11 Dec 2017 5:11PM $0.595 $0.014 fallen by 97.65%
$3 United States Patent Allowance for Core Cynata Technology 7 Dec 2017 2:24PM $0.620 $0.014 fallen by 97.74%
$3 Appendix 3Y-Paul Wotton 20 Nov 2017 8:23AM $0.605 $0.014 fallen by 97.69%
$3 Appendix 3B 20 Nov 2017 8:23AM $0.605 $0.014 fallen by 97.69%
$3 Results of Annual General Meeting 17 Nov 2017 10:17AM $0.610 $0.014 fallen by 97.70%
$3 Managing Director's Annual General Meeting Presentation 17 Nov 2017 8:41AM $0.650 $0.014 fallen by 97.85%
$3 Chairman's Annual General Meeting Address 17 Nov 2017 8:40AM $0.650 $0.014 fallen by 97.85%
$3 Company Investor Presentation 15 Nov 2017 10:08AM $0.655 $0.014 fallen by 97.86%
$3 Enrolment Completed in 1st Cohort of Cynata Clinical Trial 15 Nov 2017 9:08AM $0.645 $0.014 fallen by 97.83%
$3 September 2017 Quarterly Report 27 Oct 2017 6:45PM $0.620 $0.014 fallen by 97.74%
$3 Van Leeuwenhoeck Institute Updates Cynata Research Coverage 11 Oct 2017 9:43AM $0.630 $0.014 fallen by 97.78%
$3 Annual Report to Shareholders 9 Oct 2017 5:18PM $0.660 $0.014 fallen by 97.88%
$3 Notice of Annual General Meeting/Proxy Form 9 Oct 2017 5:16PM $0.660 $0.014 fallen by 97.88%
$3 Cynata to Increase Exposure in Japan 9 Oct 2017 9:51AM $0.645 $0.014 fallen by 97.83%
$3 US Patent Granted for Cynata Cymerus Technology 27 Sep 2017 11:03AM $0.655 $0.014 fallen by 97.86%
$3 HC Wainwright & Co Updates Cynata Research Coverage 11 Sep 2017 8:41AM $0.565 $0.014 fallen by 97.52%
$3 Cynata to Present at Rodman & Renshaw Investor Conference 5 Sep 2017 9:31AM $0.550 $0.014 fallen by 97.45%
$3 Health Canada Meeting Advances CYP Global Development Plans 31 Aug 2017 11:16AM $0.560 $0.014 fallen by 97.50%
$3 Appendix 4G 24 Aug 2017 6:45PM $0.580 $0.014 fallen by 97.59%

551 - 575 of 715 results

Page 23 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.